Swiss pharmaceutical company Novartis says it plans to invest $500 million (SFr483 million) in Russia over a five-year period.
This content was published on
1 minute
swissinfo.ch and agencies
Novartis says the investment will include the construction of a drug production plant in the western city of St Petersburg as well as research and development partnerships with local companies.
The Basel-based company says construction of the plant starts in 2011. It will be used to produce 1.5 billion generic and proprietary drugs each year when completed.
Novartis says the investment is one of the biggest it has ever made in local manufacturing.
Shares in the company rose 0.4 per cent to SFr56.95 ($58.85) on the Zurich exchange during early trading on Monday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis found guilty of sex discrimination
This content was published on
At the end of a six-week trial on Monday it awarded compensatory damages of $3.3 million (SFr3.74 million) to 12 women, and punitive damages to a larger group. The class action lawsuit – representing 5,600 women – alleged that the women were discriminated against in the areas of pay, promotions, and pregnancy-related matters. They are…
This content was published on
Pharmaceutical company Novartis paid $422 million (SFr420 million) in September, the same month that engineering concern ABB handed over $58.3 million. Zurich Financial Services paid $455 million in October, which means that Swiss bank UBS is not alone in losing out on the US market. UBS was handed a penalty of $780 million in a…
This content was published on
Net sales were up by nine per cent to $41.5 billion on accelerating growth in the Pharmaceuticals divisions as well as “important contributions” from the Vaccines and Diagnostics business and Consumer Health. “Thanks to successful innovation and a leading market position of our healthcare business portfolio, Novartis achieved a strong performance in 2008,” commented Novartis…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.